NEKTAR THERAPEUTICS
For the period ended Jun 30, 2026. Filed Aug 14, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 14, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
(c) Director and Section 16 Officer Trading Arrangements and Policies
Howard W. Robin, our President and Chief Executive Officer, previously entered into a pre-arranged stock trading plan intended to satisfy the affirmative defense of Rule10b5-1(c) under the Exchange Act on March 13, 2026, which provided for the sale of up to an aggregate 20,000 shares of the Company’s common stock (comprised of previously vested restricted stock). The plan terminated on June 17, 2026 upon completion ofall transactions thereunder.
Jonathan Zalevsky, Ph.D., our Chief Research and Development Officer, previously entered into a pre-arranged stock trading plan intended to satisfy the affirmative defense of Rule10b5-1(c) under the Exchange Act on March 13, 2026, which provided for the sale of up to an aggregate 11,219 shares of the Company’s common stock (comprised of previously vested restricted stock units). The plan terminated on June 30, 2026, upon completion of all transactions thereunder.
In the fiscal quarter ended June 30, 2026, no other directors or Section 16 officers of the Company adopted, modified, or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement” as each term is defined in Item 408 of Regulation S-K.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.